Glimicov M Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg in a sustained-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic control. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. The sustained-release formulation ensures a gradual release of active ingredients, promoting better gastrointestinal tolerability and improved patient compliance through once-daily dosing. Glimicov M Tablet SR should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular blood glucose monitoring. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in those with severe renal dysfunction, metabolic acidosis, or diabetic ketoacidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, while hypoglycemia risk is primarily associated with Glimepiride. Regular monitoring of blood glucose and renal function is recommended during therapy to ensure safety and efficacy.